Stock Track | BioCryst Shares Plunge Despite Record Q3 Revenue on Earnings Miss

Stock Track11-04

BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) saw its shares plummet over 6% in pre-market trading on November 4, 2024, after the company reported mixed third-quarter financial results. While BioCryst achieved record revenue, driven by strong sales of its flagship product ORLADEYO, the company's earnings missed analysts' expectations, prompting the sell-off.

For the third quarter ended September 30, 2024, BioCryst reported a GAAP net loss of $14.0 million, or $0.07 per share, falling short of analysts' consensus estimate of a $0.06 loss per share. This marked a significant improvement from the $36.1 million loss, or $0.19 per share, recorded in the same period last year.

Despite the earnings miss, BioCryst's revenue surged 35.1% year-over-year to $117.1 million, exceeding analysts' expectations. The company's ORLADEYO net revenue, which accounts for the majority of its sales, grew an impressive 35.7% to $116.3 million, driven by strong patient demand and continued market penetration.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1154571416?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-04 22:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1154571416","market":"hk","top_or_hot":-1,"title":"Stock Track | BioCryst Shares Plunge Despite Record Q3 Revenue on Earnings Miss","media":"Stock Track","content":"<p>BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) saw its shares plummet over 6% in pre-market trading on November 4, 2024, after the company reported mixed third-quarter financial results. While BioCryst achieved record revenue, driven by strong sales of its flagship product ORLADEYO, the company's earnings missed analysts' expectations, prompting the sell-off.</p>\n\n<p>For the third quarter ended September 30, 2024, BioCryst reported a GAAP net loss of $14.0 million, or $0.07 per share, falling short of analysts' consensus estimate of a $0.06 loss per share. This marked a significant improvement from the $36.1 million loss, or $0.19 per share, recorded in the same period last year.</p>\n\n<p>Despite the earnings miss, BioCryst's revenue surged 35.1% year-over-year to $117.1 million, exceeding analysts' expectations. The company's ORLADEYO net revenue, which accounts for the majority of its sales, grew an impressive 35.7% to $116.3 million, driven by strong patient demand and continued market penetration.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BioCryst Shares Plunge Despite Record Q3 Revenue on Earnings Miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BioCryst Shares Plunge Despite Record Q3 Revenue on Earnings Miss\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-04 22:33 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) saw its shares plummet over 6% in pre-market trading on November 4, 2024, after the company reported mixed third-quarter financial results. While BioCryst ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BCRX","symbol_name":"BioCryst制药","start_time":0,"source_url":"","article_id":"1154571416","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1154571416","pubTimestamp":1730730828,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"BioCryst Pharmaceuticals Inc.  saw its shares plummet over 6% in pre-market trading on November 4, 2024, after the company reported mixed third-quarter financial results. While BioCryst achieved record revenue, driven by strong sales of its flagship product ORLADEYO, the company's earnings missed analysts' expectations, prompting the sell-off.For the third quarter ended September 30, 2024, BioCryst reported a GAAP net loss of $14.0 million, or $0.07 per share, falling short of analysts' consensu","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BCRX":"BioCryst制药"},"translate_title":"尽管第三季度营收创历史新高，但BioCryst股价仍暴跌","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCRX":1},"content_text":"BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) saw its shares plummet over 6% in pre-market trading on November 4, 2024, after the company reported mixed third-quarter financial results. While BioCryst achieved record revenue, driven by strong sales of its flagship product ORLADEYO, the company's earnings missed analysts' expectations, prompting the sell-off.\nFor the third quarter ended September 30, 2024, BioCryst reported a GAAP net loss of $14.0 million, or $0.07 per share, falling short of analysts' consensus estimate of a $0.06 loss per share. This marked a significant improvement from the $36.1 million loss, or $0.19 per share, recorded in the same period last year.\nDespite the earnings miss, BioCryst's revenue surged 35.1% year-over-year to $117.1 million, exceeding analysts' expectations. The company's ORLADEYO net revenue, which accounts for the majority of its sales, grew an impressive 35.7% to $116.3 million, driven by strong patient demand and continued market penetration.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1154571416"}